Literature DB >> 24012346

Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ.

Pietro Invernizzi1.   

Abstract

The study of the liver as a lymphoid organ is a growing field fueled by our better knowledge of the different component of the immune system and how they orchestrate an immune-related response. The liver have highly specialized mechanisms of immune tolerance, mainly because is continuously exposed to microbial and environmental antigens, and dietary components from the gut. Accordingly, the liver contains specialized lymphoid subpopulations acting as antigen-presenting cells. Growing evidences show that the liver is also associated with obesity-associated diseases because of its immune-related capacity to sense metabolic stress induced by nutritional surplus. Finally, the liver produces a pletora of neo-antigens being the primary metabolic organ of the body. Common immune mechanisms play a key pathogenetic role in most of acute and chronic liver diseases and in the rejection of liver allografts. Any perturbations of liver-related immune functions have important clinical implications. This issue of the Journal of Autoimmunity is focused on the more recent advances in our knowledge related to the loss of liver tolerance, a paradox for a tolerogenic organ, that leads to overactivation of the innate and adaptive immune response and the development of autoimmune liver diseases, such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis. The invited expert review articles capture the underlying immunomolecular mechanisms of the development and progression of autoimmune liver diseases, the novel field of the immune-related "liver-gut" axis influences to the development of liver autoimmunity, the predominant role of genetic factors, and the increasingly effective immuno-therapeutic possibilities.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Liver immunology

Mesh:

Year:  2013        PMID: 24012346     DOI: 10.1016/j.jaut.2013.08.006

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  17 in total

Review 1.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 2.  Environmental Basis of Autoimmunity.

Authors:  Annarosa Floreani; Patrick S C Leung; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

3.  Preemptive Tolerogenic Delivery of Donor Antigens for Permanent Allogeneic Islet Graft Protection.

Authors:  Shusen Wang; Xiaomin Zhang; Lei Zhang; Jane Bryant; Taba Kheradmand; Bernhard J Hering; Stephen D Miller; Xunrong Luo
Journal:  Cell Transplant       Date:  2014-04-22       Impact factor: 4.064

4.  Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease?

Authors:  Antonio Maria Alfano; Alessandra Romito; Cristiana Marchese; Marco Battistini; Giliola Crotti; Arturo Ferrini; Cristina Mancinetti; Tilde Manetta; Giulio Mengozzi; Paola Merlach; Marco Migliardi; Maria Teresa Tambuzzo
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

5.  Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells.

Authors:  H Tanaka; W Zhang; G-X Yang; Y Ando; T Tomiyama; K Tsuneyama; P Leung; R L Coppel; A A Ansari; Z X Lian; W M Ridgway; T Joh; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

6.  Trichloroethylene Exposure Reduces Liver Injury in a Mouse Model of Primary Biliary Cholangitis.

Authors:  Jessica L Ray; Anna K Kopec; Nikita Joshi; Holly Cline-Fedewa; Lawrence H Lash; Kurt J Williams; Patrick S Leung; M Eric Gershwin; James P Luyendyk
Journal:  Toxicol Sci       Date:  2017-04-01       Impact factor: 4.849

Review 7.  Proposed therapies in primary biliary cholangitis.

Authors:  Annarosa Floreani; Ying Sun; Zheng Sheng Zou; Baosen Li; Nora Cazzagon; Christopher L Bowlus; M Eric Gershwin
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-01-06       Impact factor: 3.869

Review 8.  The diagnosis of primary biliary cirrhosis.

Authors:  Christopher L Bowlus; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2014-01-11       Impact factor: 9.754

9.  Extrahepatic malignancies in primary biliary cirrhosis: a comparative study at two European centers.

Authors:  Annarosa Floreani; Alice Spinazzè; Llorenc Caballeria; Ana Reig; Nora Cazzagon; Irene Franceschet; Alessandra Buja; Patrizia Furlan; Kenichi Harada; Patrick Sc Leung; M Eric Gershwin; Albert Pares
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 10.  The Potential Roles of Bisphenol A (BPA) Pathogenesis in Autoimmunity.

Authors:  Datis Kharrazian
Journal:  Autoimmune Dis       Date:  2014-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.